{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-013495","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2025-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.925454+00:00","generated_at":"2026-05-17T06:36:42.000334+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cocrystal Pharma closes $4.7M registered direct offering with warrant coverage","bullets":["Gross proceeds of ~$4.75M from sale of 2,764,710 shares at $1.70 each.","Warrants issued to purchase 5,529,420 shares at $1.50, potential additional $8.3M.","Net proceeds for working capital and antiviral drug development.","H.C. Wainwright acted as placement agent; warrants expire 24 months after resale registration effective."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-013495","json":"https://secwatch.observer/filing/0001493152-25-013495.json","markdown":"https://secwatch.observer/filing/0001493152-25-013495.md","text":"https://secwatch.observer/filing/0001493152-25-013495.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315225013495/0001493152-25-013495-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315225013495/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:36:42.000334+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1606916374dedef3f9154407e7a3ceab855ff469","claim":"Cocrystal Pharma, Inc. issued 2,764,710 shares of common stock to accredited investors for at a price of $1.70 per share.","evidence_excerpt":"in a registered direct offering, an aggregate of 2,764,710 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price of $1.70 per share (the “Registered Direct Offering”) and (ii) in a concurrent private placement, warrants to purchase up to an aggregate of 5,529,420 shares of Comon Stock (“the Investor","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315225013495/0001493152-25-013495-index.htm","confidence":0.95,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"2,764,710 shares"},{"label":"Purchaser","value":"accredited investors"},{"label":"Consideration","value":"at a price of $1.70 per share"}],"fact_type":"equity_issuance"},{"claim_id":"d81d34f25c06c9ca301c179196abb76ee57a47e0","claim":"Cocrystal Pharma, Inc. issued warrants to purchase up to an aggregate of 5,529,420 shares of warrant to accredited investors for initial exercise price of $1.50 per share.","evidence_excerpt":"and (ii) in a concurrent private placement, warrants to purchase up to an aggregate of 5,529,420 shares of Comon Stock (“the Investor Warrants”), at an initial exercise price of $1.50 per share (the “Private Placement” and together with the Registered Direct Offering, the “Offering”). The Shares were offered at-the-market under rules of The Nasdaq Stock Market,","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315225013495/0001493152-25-013495-index.htm","confidence":0.95,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"warrants to purchase up to an aggregate of 5,529,420 shares"},{"label":"Purchaser","value":"accredited investors"},{"label":"Consideration","value":"initial exercise price of $1.50 per share"}],"fact_type":"equity_issuance"},{"claim_id":"e12d388d61efc689aec2e456c67c76f08cb2275b","claim":"Cocrystal Pharma, Inc. issued warrants to acquire up to an aggregate of 207,353 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC for cash fee equal to 7.0% of the aggregate gross proceeds, a management fee equal to 1.0% of the aggregate gross proceeds, reimbursement of certain expenses.","evidence_excerpt":"medicines for use in the treatment of human viral diseases. 2 Under the SPA, no later than October 10, 2025, the Company is required to file a registration statement on Form S-1 registering the resale of the shares of Common Stock issued or issuable upon exercise of the Investor Warrants (the “Resale Registration Statement”). The Company is required to","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315225013495/0001493152-25-013495-index.htm","confidence":0.95,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"warrants to acquire up to an aggregate of 207,353 shares of Common Stock"},{"label":"Purchaser","value":"H.C. Wainwright & Co., LLC"},{"label":"Consideration","value":"cash fee equal to 7.0% of the aggregate gross proceeds, a management fee equal to 1.0% of the aggregate gross proceeds, reimbursement of certain expenses"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}